- Home
- LVTX vs BOLT Comparison
LVTX vs BOLT Comparison
Compare LVTX & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- BOLT
- Stock Information
- Founded
- LVTX 2016
- BOLT 2015
- Country
- LVTX Netherlands
- BOLT United States
- Employees
- LVTX N/A
- BOLT N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- BOLT Health Care
- Exchange
- LVTX Nasdaq
- BOLT Nasdaq
- Market Cap
- LVTX 27.9M
- BOLT 22.6M
- IPO Year
- LVTX 2021
- BOLT 2021
- Fundamental
- Price
- LVTX $1.02
- BOLT $0.57
- Analyst Decision
- LVTX Buy
- BOLT Hold
- Analyst Count
- LVTX 3
- BOLT 5
- Target Price
- LVTX $3.33
- BOLT $1.25
- AVG Volume (30 Days)
- LVTX 208.1K
- BOLT 203.6K
- Earning Date
- LVTX 12-10-2024
- BOLT 11-12-2024
- Dividend Yield
- LVTX N/A
- BOLT N/A
- EPS Growth
- LVTX N/A
- BOLT N/A
- EPS
- LVTX N/A
- BOLT N/A
- Revenue
- LVTX $7,345,000.00
- BOLT $9,779,000.00
- Revenue This Year
- LVTX N/A
- BOLT $9.87
- Revenue Next Year
- LVTX N/A
- BOLT N/A
- P/E Ratio
- LVTX N/A
- BOLT N/A
- Revenue Growth
- LVTX N/A
- BOLT 35.86
- 52 Week Low
- LVTX $0.88
- BOLT $0.48
- 52 Week High
- LVTX $6.47
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- LVTX 37.42
- BOLT 50.51
- Support Level
- LVTX $0.95
- BOLT $0.49
- Resistance Level
- LVTX $1.04
- BOLT $0.63
- Average True Range (ATR)
- LVTX 0.08
- BOLT 0.05
- MACD
- LVTX 0.03
- BOLT 0.01
- Stochastic Oscillator
- LVTX 58.16
- BOLT 58.19
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.